Press release
Dry Age Macular Degeneration Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight
"Dry Age Macular Degeneration Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Age Macular Degeneration Market.
The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Dry Age Macular Degeneration Pipeline Report: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies with a considerable amount of success over the years.
• Dry Age Macular Degeneration companies working in the treatment market are Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Novartis, Alkeus Pharmaceuticals, Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, and others, are developing therapies for the Dry Age Macular Degeneration treatment
• Emerging Dry Age Macular Degeneration therapies in the different phases of clinical trials are- IZERVAY (avacincaptad pegol), SYFOVRE (pegcetacoplan), Iptacopan (LNP023), ALK-001, Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others are expected to have a significant impact on the Dry Age Macular Degeneration market in the coming years.
• Potential therapies expected to drive notable changes during the upcoming forecast period include AVD-104, Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, ANX007, Danicopan (ALXN2040), IONIS-FB-LRx (RG6299), JNJ-1887, CPCB-RPE1, OpRegen, and others.
• In April 2026, The long-term analysis of the GATHER2 study further demonstrated the sustained efficacy of avacincaptad pegol over a two-year period, reinforcing its potential to slow disease progression in patients with geographic atrophy.
• In March 2026, Ocugen's OCU410 (AAV5-RORA) in the Phase II ArMaDa trial showed positive 12-month topline results. The gene therapy demonstrated a statistically significant reduction in geographic atrophy lesion growth compared with the control group and was generally well tolerated, showing a favorable safety profile. The company is preparing for Phase III development.
• In December 2025, In the GATHER2 trial, two-year Phase III results for izervay (avacincaptad pegol) showed a continued and sustained reduction in geographic atrophy lesion progression, along with an acceptable safety profile. These findings further reinforce the therapeutic value of complement inhibition in the treatment of dry age-related macular degeneration (AMD).
• In September 2025, The RPESC-RPE-4W stem cell therapy in a Phase I/IIa study showed encouraging outcomes in a first-in-human trial conducted by Luxa Biotechnology. Patients with advanced vision impairment experienced meaningful improvements in visual acuity, supporting further development of retinal pigment epithelial stem cell-based approaches for treating dry age-related macular degeneration (AMD).
• In February 2025, Luxa Biotechnology announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). The company is developing this innovative adult retinal pigment epithelial stem cell therapy for patients with dry AMD.
• In November 2024, The U.S. FDA approved LumiThera's Valeda Light Delivery System for marketing as a treatment for dry age-related macular degeneration (AMD).
Dry Age Macular Degeneration Overview
Dry age-related macular degeneration (AMD) involves a gradual breakdown of macular cells over an extended period. This occurs as retinal cells decline without renewal. It's important to note that the term 'dry' doesn't imply dry eyes but rather distinguishes it from wet AMD.
Get a Free Sample PDF Report to know more about Dry Age Macular Degeneration Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Dry Age Macular Degeneration Drugs Under Different Phases of Clinical Development Include:
• IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
• SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
• Iptacopan (LNP023): Novartis
• ALK-001: Alkeus Pharmaceuticals
• Tinlarebant (LBS-008): Belite Bio
• XIFLAM: Inflammx Therapeutics
• OCU410: Ocugen
• OLX301A: OliX Pharmaceuticals
• GS030: Gensight Biologics
Dry Age Macular Degeneration Route of Administration
Dry Age Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Dry Age Macular Degeneration Molecule Type
Dry Age Macular Degeneration Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Dry Age Macular Degeneration Pipeline Therapeutics Assessment
• Dry Age Macular Degeneration Assessment by Product Type
• Dry Age Macular Degeneration By Stage and Product Type
• Dry Age Macular Degeneration Assessment by Route of Administration
• Dry Age Macular Degeneration By Stage and Route of Administration
• Dry Age Macular Degeneration Assessment by Molecule Type
• Dry Age Macular Degeneration by Stage and Molecule Type
DelveInsight's Dry Age Macular Degeneration Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Dry Age Macular Degeneration product details are provided in the report. Download the Dry Age Macular Degeneration pipeline report to learn more about the emerging Dry Age Macular Degeneration therapies
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Dry Age Macular Degeneration Therapeutics Market include:
Key companies developing therapies for Dry Age Macular Degeneration are - Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, and others.
Dry Age Macular Degeneration Pipeline Analysis:
The Dry Age Macular Degeneration pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dry Age Macular Degeneration with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.
• Dry Age Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dry Age Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age Macular Degeneration market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dry Age Macular Degeneration drugs and therapies
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Dry Age Macular Degeneration Pipeline Market Drivers
• Growing aging population worldwide is increasing the prevalence of Dry AMD, expanding the target patient pool.
• Significant unmet medical need due to limited treatment options for geographic atrophy and advanced Dry AMD is driving pipeline innovation.
• Advancements in complement pathway inhibitors, gene therapies, and regenerative medicine approaches are creating new therapeutic opportunities.
• Increasing investment in ophthalmology research and clinical development is accelerating the progression of promising pipeline candidates
Dry Age Macular Degeneration Pipeline Market Barriers
• Complex disease pathophysiology makes the development of effective disease-modifying therapies challenging.
• Lengthy and costly clinical trials are required to demonstrate meaningful visual and anatomical benefits.
• Stringent regulatory requirements may delay the approval and commercialization of emerging therapies.
• Variability in patient response and disease progression can complicate clinical trial outcomes.
Scope of Dry Age Macular Degeneration Pipeline Drug Insight
• Coverage: Global
• Key Dry Age Macular Degeneration Companies: Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Novartis, Alkeus Pharmaceuticals, Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, and others
• Key Dry Age Macular Degeneration Therapies: IZERVAY (avacincaptad pegol), SYFOVRE (pegcetacoplan), Iptacopan (LNP023), ALK-001, Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others
• Dry Age Macular Degeneration Therapeutic Assessment: Dry Age Macular Degeneration current marketed and Dry Age Macular Degeneration emerging therapies
• Dry Age Macular Degeneration Market Dynamics: Dry Age Macular Degeneration market drivers and Dry Age Macular Degeneration market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age Macular Degeneration Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight here
News-ID: 4542669 • Views: …
More Releases from DelveInsight Business Research
Esophageal Cancer Market Expected to Experience Accelerated Growth and Market Ev …
DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast
https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Alopecia Areata Market Unlocking New Revenue Opportunities and Strategic Expansi …
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.
DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United…
Burns Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and RO …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Burns pipeline constitutes 12+ key companies continuously working towards developing 12+ Burns treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Burns Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description…
Diabetic Kidney Disease Market Forecast Signals Robust Industry Growth Through 2 …
DelveInsight's "Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Diabetic Kidney Disease, offering comprehensive insights into the Diabetic Kidney Disease revenue trends,…
More Releases for Dry
Dry Fruits Mart Expands Its Premium Dry Fruits and Organic Products Line Across …
Dry Fruits Mart has officially announced the nationwide expansion of its premium dry fruits and organic product line across Pakistan, responding to the growing demand for high-quality, natural, and nutrient-rich food products. The expansion reflects the brand's continued growth and commitment to serving customers who prioritize healthier lifestyle choices.
More information about the company and its complete product portfolio is available at: https://dryfruitsmart.pk/
As part of this development, the company has…
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
